The Chinese patent office, the State Intellectual Property Office, has formally approved the company’s patent application for IL1RAP as target molecule for antibody therapy of several types of solid tumours.

Cantargia is developing antibodies against IL1RAP for treatment of life-threatening diseases. The company’s main project, the immuno-oncology antibody CAN04, which Nordic Life Science previously has reported on, is undergoing a clinical phase I/IIa trial focusing on treatment of non-small cell lung cancer and pancreatic cancer.

The patent application which has now been approved in China refers to Cantargia’s method of using IL1RAP as target molecule for treatment of several types of solid tumours, including breast cancer, colorectal cancer, lung cancer and malignant melanoma. Cantargia already has the equivalent patent protection in other regions, including Europe, the United States and Japan.

Protection until 2032

The Chinese patent provides protection until 2032.

“Cantargia has strong protection for antibodies against IL1RAP for treatment of cancer in several important territories. The addition of China, which is one of the fastest growing markets for pharmaceuticals, further strengthens our position,” says Göran Forsberg, Cantargia’s CEO.

Read more about Cantargia’s journey and business development here:

Business in focus: Cantargia